Skip to main content
. Author manuscript; available in PMC: 2020 Dec 21.
Published in final edited form as: Oncogene. 2020 Jun 21;39(31):5390–5404. doi: 10.1038/s41388-020-1370-9

Figure 1: Integrin α6β1 and Bnip3 are elevated in CRPC.

Figure 1:

A) Expression of integrin α6 (ITGα6), integrin β1 (ITGβ1), and BNIP3 mRNA in castration-resistant (CR) human-derived xenografts (PDX) of LuCaP 23.1 and LuCaP 35 normalized to expression in androgen-sensitive respective parental tumors. B) Levels of androgen receptor (AR), integrin α6 (ITGα6), integrin β1 (ITGβ1), integrin β4 (ITGβ4), Bnip3, PSA, and tubulin in laminin-adherent LNCaP, C4–2, and C4–2B cells treated with (+) or without (-) 10nM R1881 for 24 h as assessed by immunoblotting. C) Levels of Bnip3 mRNA in laminin-adherent LNCaP and C4–2 cells treated with (+) or without (-) 10nM R1881 for 24 h as measured by qRT-PCR. D) Levels of Bnip3 expression in androgen-sensitive vs castrate-resistant (CR) LuCaP PDX tumors as assessed by IHC. LuCaP 35/CR, LuCaP 77/CR, LuCaP 105/CR, and LuCaP 86.2/CR. E) C4–2, C4–2B, and LNCaP cells adherent to laminin treated with (+) or without (-) 10nM R1881 for 24 h and the levels of HIF1α, HIF2α, Bnip3, Bcl-XL, and tubulin assessed by immunoblotting. *p<0.05, **p<0.01, ***p< 0.005, n=3 biological replicates, error bars = SD